X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Aphena Adds Cold Chain Storage, Biologics Packaging and Distribution to Its Offerings

Content Team by Content Team
16th November 2020
in News, Packaging & Logistic
Aphena Adds Cold Chain Storage, Biologics Packaging and Distribution to Its Offerings

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Aphena Pharma Solutions announces that it now offers cold chain storage and large-scale biologics packaging and distribution in a new, 500,000-square-foot property that is purpose-built for FDA manufacturing and packaging operations. This new facility is part of the company’s recently announced $21 million expansion of its Solid Dose Division in Tennessee.

Within that new space, Aphena has dedicated 47,000 square feet to cold chain storage, with 14,000 pallet spaces available. This space features 24-hour, state-of-the-art security; redundant power supplies with a failover compressor; temperature mapping and monitoring; automatic alarm notification; and chilled storage and distribution with temperatures ranging from 2º C to 8º C refrigerated and -10º C to -18º C frozen.

“This addition of cold chain storage, turnkey biologics packaging and distribution services establishes Aphena’s position as a top contender in the pharmaceutical contract service space,” said Eric Allen, Aphena’s EVP of Sales. “These new service offerings, on top of our recently expanded solids and liquids operations, will continue to bring added value to future and current customers worldwide.”

An additional benefit of Aphena locating its cold chain storage and biologics operations in Tennessee, the distribution hub of the U.S., is that it is less than 500 miles away from 75% of the U.S. population.

“Aphena is very excited to announce this new level of offerings to better serve our customers with expanded project capabilities at every level,” said Aphena CEO Shawn Reilley. “This addition effectively makes Aphena the largest provider of cold chain storage and one of the most diversified manufacturing and packaging companies in the pharmaceutical industry.”

Aphena Pharma Solutions is an industry-leading organization providing contract manufacturing and packaging services for the biologics, pharmaceutical, consumer health and medical device markets. With two separate FDA- and DEA-registered locations in the U.S., Aphena handles solid dose, liquids, gels, creams, ointments, foams, suspensions and lotion-based products.

Previous Post

Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients

Next Post

Ypsomed collaborates with SCHOTT and Lonza to develop a comprehensive solution for combination products based on patch injectors

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Ypsomed collaborates with SCHOTT and Lonza to develop a comprehensive solution for combination products based on patch injectors

Ypsomed collaborates with SCHOTT and Lonza to develop a comprehensive solution for combination products based on patch injectors

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In